Algernon Pharmaceuticals Inc. C.AGN

Question for Whalewatcher

[nodaytrader]

If I read it right, you are arguing that NASDAQ bases its eligibility criteria on data from CSE.
My question is "why would they do that?"
NASDAQ's trading volume is about US$200 billion a day. CSE's is about CAN$20 million on a good day. So, NASDAQ is 10,000 times bigger.
NASDAQ operates in the US market, which is much bigger than CSE's Canadian market.
Presumably, NASDAQ has the data, experience and knowledge to reach its own conclusions about the value of a company in its own market.
so why would it base its eligibility requirements on data from a relatively tiny exchange, in a much smaller market, that has comparatively little knowledge of the US market?

[C10H12N2]

What you just said needs to be framed here. Thanks for that EZ to follow along example.

[Whalewatcher1]

C10H12N2, my point is simply that the company is currently publicly traded on CSE and OTC. When uplist to Nasdaq, you don't set a new price irrespective of past trading. Share price is based on price of last trade. I.e. today shares closed at $3.26 on OTC, if Nasdaq listing was effective tomorrow then Nasdaq price would be based on $3.26. if company was private, then yes, can set price at

[C10H12N2]

We hear you. i simply believe you are flat out wrong. you keeo talking about look at other companies. I don't have to. I'm looking at and comprehending the NASDAQ Guidelines. The same guidelines you are continue going outside of to come up with your own theories. including the Andre Uddin hitman guy who pumped Algernon for the PP then dumped on Algernon when it reported it's first

[Whalewatcher1]

I could be wrong. But if you go look up for youself how stocks trade post Nasdaq listing. CSE/TSXV listed stocks never double or so just because they list on Nasdaq . . . We both agree that they need $15M US market cap. I just dont believe that management has a proper grasp on the steps/requiremetns to uplist and becomes another example of setting guidance that cant be reallistically achieved

[C10H12N2]

ROTFLMAO. You don’t believe they have an understanding of the uplist. Meanwhile, you need to be pointed to the correct page of the Nasdaq Guidelines. Now you're an expert based on Andre Uddin (yeah, you talked to him today) and your pick of stocks out in the world as a supposed quantifier of facts. Around in circles you go. Where you stop nobody knows. Nodayrader gave you a clear understanding

[Whalewatcher1]

Just trying to get to the truth, would you really trust talking with algernon management on this topic? Based on your earlier comments i think the answer is an obvious NO.   I just think you are misleading others on this thread. Do you really think there will be a total re-evaluation of the value of share price with Nasdaq listing and then CSE share magically double?  If so, you are in

[C10H12N2]

I say exactly what I think. Always have and always will. You apparently know Jack shii about me. Your personal attack is unwarranted. That's what I get for trying to help you better understand the situation. Spent all day and this is the thanks I get from you. You prove a primary reason why the company must to get as far away from penny flippers as possible. You can't even be reasonable

[Whalewatcher1]

You should check out the streetwise report on algernon today. Keep in mind that algernon pays for this report. Chris provides examples of Nasdaq up listing  in xortx and Diamedica, neither worked out for investors. Xortx just uplisted- was trading at $6 early October on CSE, raised $12m at $4 (typical discount) a share early October and now trades at below $2, but is Nasdaq listed. Nasdaq

[C10H12N2]

What I think is Whalewatcher1 is an ALL OUT CLOWN. Neither XORTX or Diamedica Therapeutics have any drugs in their pipeline that matches up with Algernon Pharmaceuticals. Try at least matching apples to apples - DMT - Chronic Cough - Small Cell Lung Cancer. Those are the diseases currently on the plate for debate. As to whatever Moreau may or may not have said about either of those companies, we

[Whalewatcher1]

C10H12N2, what's with calling me clown? I'm just pointing out recent case studies of what happens when CSE or TSXV biotechs uplist to Nasdaq and how stock prices plummeted. This is contrary to what you are saying. I'd love to get your perspective? In terms of the othe companies, I don't know what they do but they both have capital to run clinical studies, looks like Algernon needs

[C10H12N2]

What I think is you are a clown and should direct your posts to someone else. What I think beyond your clownship is irrelevant in these back and forth threads with you.  Hence, I am blocking your posts ASAP because I find none of them helpful to anyone and especially to me. I lose brain cells ranting back and forth with you. Henceforth, speak to the wind child.

[TheBearInTheWoods]

Well put Whale, you can't fake it to the Nasdaq by putting lipstick on a pig with a 100-1 consolidation and think the market will reward you.  No patents + No money = .04 share price just like Xrtx , only a licensed drug .... sound familiar?   

[nodaytrader]

Thank you for clarifying the NASDAQ requirements which had been confusing me.